COMPASS Pathways

The company's primary drug candidate is COMP360, a proprietary, high-purity crystalline formulation of psilocybin administered in conjunction with psychological support from trained therapists. This model is currently undergoing a global Phase 3 clinical program, the largest of its kind for a psilocybin treatment. COMP360 has received "Breakthrough Therapy" designation from the U.S. Food and Drug Administration (FDA), which is intended to expedite the development of drugs for serious conditions. The company's business model is centered on the clinical development, regulatory approval, and eventual commercialization of its therapies. Revenue is expected to be generated through future sales of approved treatments, licensing agreements, and partnerships.

Originally started as a non-profit, COMPASS transitioned to a for-profit entity to secure the substantial funding required for extensive clinical trials. This shift enabled the company to raise significant capital, including an $80 million Series B round in April 2020 and a successful IPO on the NASDAQ in September 2020, which raised $146.6 million. The company has attracted funding from notable investors such as Peter Thiel's Founders Fund, ATAI Life Sciences, and McQuade Center for Strategic Research and Development. In March 2024, co-founders George Goldsmith and Ekaterina Malievskaia stepped down from the board of directors as a natural evolution of the company's growth into a mature public entity focused on late-stage clinical development.